Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Design Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 125
- +9 vs. Q4 2025
- Shares held
- 38.0M
- +1.50M (+4.1%) vs. Q4 2025
- Total value
- $404.1M
- +$61.9M (+18.1%) vs. Q4 2025
- New holders
- 22
- 56 more added
- Sold out
- 13
- 28 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DSGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 136 | $626.4M |
| Q1 2026 | 125 | $404.1M |
| Q4 2025 | 117 | $357.6M |
| Q3 2025 | 95 | $259.7M |
| Q2 2025 | 93 | $116.4M |
| Q1 2025 | 98 | $133.0M |
| Q4 2024 | 95 | $206.5M |
| Q3 2024 | 100 | $172.3M |
| Q2 2024 | 95 | $107.5M |
| Q1 2024 | 93 | $123.9M |
| Q4 2023 | 88 | $84.0M |
| Q3 2023 | 87 | $77.6M |
| Q2 2023 | 97 | $244.4M |
| Q1 2023 | 96 | $223.3M |
| Q4 2022 | 83 | $414.2M |
| Q3 2022 | 79 | $667.2M |
| Q2 2022 | 74 | $541.7M |
| Q1 2022 | 63 | $613.7M |
| Q4 2021 | 60 | $773.1M |
| Q3 2021 | 52 | $414.8M |
| Q2 2021 | 50 | $546.2M |
| Q1 2021 | 43 | $755.2M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Design Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kennedy Capital Management, Inc. | 271,554 | $2.89M | 0.06% | +221,531+442.9% | Added |
| Jacobs Levy Equity Management, Inc | 289,385 | $3.08M | 0.01% | +94,774+48.7% | Added |
| Northern Trust Corp | 300,279 | $3.19M | 0.00% | +13,707+4.8% | Added |
| Renaissance Technologies LLC | 408,200 | $4.34M | 0.01% | +121,100+42.2% | Added |
| Dimensional Fund Advisors LP | 431,840 | $4.59M | 0.00% | +133,919+45.0% | Added |
| D. E. Shaw & Co., Inc. | 470,270 | $5.00M | 0.00% | +31,376+7.1% | Added |
| Goldman Sachs Group Inc | 504,718 | $5.37M | 0.00% | +234,064+86.5% | Added |
| Acadian Asset Management LLC | 616,481 | $6.55M | 0.01% | +3,713+0.6% | Added |
| Morgan Stanley | 656,565 | $6.99M | 0.00% | −45,741−6.5% | Reduced |
| State Street Corp | 659,575 | $7.02M | 0.00% | +11,939+1.8% | Added |
| Geode Capital Management, LLC | 692,518 | $7.37M | 0.00% | +12,928+1.9% | Added |
| Kynam Capital Management, LP | 784,606 | $8.35M | 0.53% | 00.0% | Unchanged |
| FMR LLC | 798,411 | $8.50M | 0.00% | +27,143+3.5% | Added |
| Trails Edge Capital Partners, LP | 852,013 | $9.07M | 2.13% | +852,013 | New |
| Woodline Partners LP | 961,501 | $10.2M | 0.04% | +17,462+1.8% | Added |
| Vanguard Capital Management LLC | 1,349,850 | $14.4M | 0.00% | +1,349,850 | New |
| Almitas Capital LLC | 1,530,335 | $16.3M | 3.68% | −1000.0% | Reduced |
| Vivo Capital, LLC | 1,612,903 | $17.2M | 1.43% | 00.0% | Unchanged |
| Driehaus Capital Management LLC | 1,744,987 | $18.6M | 0.14% | +565,170+47.9% | Added |
| Logos Global Management LP | 1,950,000 | $20.7M | 1.07% | −550,000−22.0% | Reduced |
| BlackRock, Inc. | 2,133,764 | $22.7M | 0.00% | +16,608+0.8% | Added |
| Baker Bros. Advisors LP | 2,585,978 | $27.5M | 0.16% | +352,879+15.8% | Added |
| Point72 Asset Management, L.P. | 2,722,754 | $29.0M | 0.05% | −2,649,250−49.3% | Reduced |
| Ra Capital Management, L.P. | 2,972,973 | $31.6M | 0.34% | +1,511,592+103.4% | Added |
| Sr One Capital Management, LP | 6,526,476 | $69.4M | 7.59% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 0 | $0 | 0.00% | −521,000−100.0% | Sold out |
| Diadema Partners LP | 0 | $0 | 0.00% | −100,320−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −61,852−100.0% | Sold out |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −34,989−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −25,300−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −22,651−100.0% | Sold out |
| 9823 Capital, L.P. | 0 | $0 | 0.00% | −19,197−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −11,728−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,396−100.0% | Sold out |
| Torren Management, LLC | 0 | $0 | 0.00% | −2,820−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −751−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −47−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |